Accordingly, pre-clinical in vitro studies have shown that AMXI-5001 exerts synergistic activity with TRAIL in several tumor cell models, advocating that the antineoplastic outcomes of PARPi might involve an improved tumor sensitization to NK cell mediated-apoptosis by TRAIL stimulation. The gene discussed is TNFSF10; the disease is neoplasm.